{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:51Z","timestamp":1791206391733,"version":"4.1.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Therapy of intracellular pathogens can be complicated by drug toxicity, drug resistance, and the need for prolonged treatment regimens. One approach that has shown promise is immunotherapy. Leishmaniasis, a vector-borne disease ranked among the six most important tropical infectious diseases by the World Health Organization, has been treated clinically with crude or defined vaccine preparations or cytokines, such as IFN-\u03b3 and GM-CSF, in combination with chemotherapy. We have attempted to develop an improved and defined immunotherapeutic using a mouse model of cutaneous leishmaniasis. We hypothesized that immunotherapy may be improved by using TLR synergy to enhance the parasite-specific immune response. We formulated L110f, a well-established Leishmania poly-protein vaccine candidate, in conjunction with either monophosphoryl lipid A, a TLR4 agonist, or CpG, a TLR9 agonist, or a combination of these, and evaluated anti-Leishmania immune responses in absence or presence of active disease. Only mice treated with L110f plus monophosphoryl lipid A-CpG were able to induce a strong effective T cell response during disease and subsequently cured lesions and reduced parasite burden when compared with mice treated with L110f and either single adjuvant. Our data help to define a correlate of protection during active infection and indicate TLR synergy to be a potentially valuable tool in treating intracellular infections.<\/jats:p>","DOI":"10.4049\/jimmunol.1000238","type":"journal-article","created":{"date-parts":[[2010,7,3]],"date-time":"2010-07-03T03:22:24Z","timestamp":1278127344000},"page":"1701-1710","source":"Crossref","is-referenced-by-count":81,"title":["Applying TLR Synergy in Immunotherapy: Implications in Cutaneous Leishmaniasis"],"prefix":"10.1093","volume":"185","author":[{"given":"Vanitha S","family":"Raman","sequence":"first","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Picone","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Whittle","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilton R","family":"Bailor","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Pattabhi","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Guderian","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raodoh","family":"Mohamath","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm S","family":"Duthie","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Reed","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute , Seattle, WA 98104"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,8,1]]},"reference":[{"key":"2025032411443950100_r1","first-page":"35","volume-title":"Scientific Working Group on Leishmaniasis Meeting Report, February 2-4.","author":"Stuart","year":"2004"},{"key":"2025032411443950100_r2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-9292-6-7","article-title":"Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis","volume":"6","author":"Ghalib","year":"2007","journal-title":"Kinetoplastid Biol. Dis."},{"key":"2025032411443950100_r3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"2025032411443950100_r4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-4632.2009.04072.x","article-title":"Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis","volume":"48","author":"Firdous","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"2025032411443950100_r5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijpara.2008.03.005","article-title":"Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII","volume":"38","author":"Choudhury","year":"2008","journal-title":"Int. J. Parasitol."},{"key":"2025032411443950100_r6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drup.2004.07.002","article-title":"Leishmaniasis: drugs in the clinic, resistance and new developments","volume":"7","author":"Ouellette","year":"2004","journal-title":"Drug Resist. Updat."},{"key":"2025032411443950100_r7","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"key":"2025032411443950100_r8","first-page":"297","article-title":"Comment on Dubovsky, P., Vaccinotherapy in cutaneous leishmaniais","volume":"40","author":"Hoare","year":"1943","journal-title":"Trop. Dis. Bull."},{"key":"2025032411443950100_r9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0738-081X(96)00040-5","article-title":"Vaccine for prophylaxis and immunotherapy, Brazil","volume":"14","author":"Genaro","year":"1996","journal-title":"Clin. Dermatol."},{"key":"2025032411443950100_r10","first-page":"259","article-title":"The present and future of vaccination for cutaneous leishmaniasis","volume":"47","author":"Greenblatt","year":"1980","journal-title":"Prog. Clin. Biol. Res."},{"key":"2025032411443950100_r11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Vaccine"},{"key":"2025032411443950100_r12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol."},{"key":"2025032411443950100_r13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/314782","article-title":"Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action","volume":"179","author":"Buates","year":"1999","journal-title":"J. Infect. Dis."},{"key":"2025032411443950100_r14","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r15","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"27","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"key":"2025032411443950100_r16","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/14760584.2.2.239","article-title":"Development of a leishmaniasis vaccine: the importance of MPL","volume":"2","author":"Reed","year":"2003","journal-title":"Expert Rev. Vaccines"},{"key":"2025032411443950100_r18","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1073\/pnas.96.12.6970","article-title":"Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms","volume":"96","author":"Walker","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411443950100_r19","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1128\/IAI.73.8.4948-4954.2005","article-title":"Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D\/A oligodeoxynucleotides expressing CpG motifs","volume":"73","author":"Flynn","year":"2005","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat. Med."},{"key":"2025032411443950100_r21","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.vaccine.2009.10.045","article-title":"Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis","volume":"28","author":"Velez","year":"2009","journal-title":"Vaccine"},{"key":"2025032411443950100_r23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"2025032411443950100_r24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/bmj.1.2671.540","article-title":"The curative value of Leishmania culture \u201cvaccine\u201d in oriental sore","volume":"1","author":"Row","year":"1912","journal-title":"Br. Med. J."},{"key":"2025032411443950100_r25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1086\/507708","article-title":"Immunotherapy for drug-refractory mucosal leishmaniasis","volume":"194","author":"Badaro","year":"2006","journal-title":"J. Infect. Dis."},{"key":"2025032411443950100_r26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1413-86702001000400008","article-title":"Successful use of a defined antigen\/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report","volume":"5","author":"Badaro","year":"2001","journal-title":"Braz. J. Infect. Dis."},{"key":"2025032411443950100_r27","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2009.03.018","article-title":"Intradermal immunization improves protective efficacy of a novel TB vaccine candidate","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"2025032411443950100_r28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"2025032411443950100_r29","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.4049\/jimmunol.147.9.3149","article-title":"IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis","volume":"147","author":"Scott","year":"1991","journal-title":"J. Immunol."},{"key":"2025032411443950100_r30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"key":"2025032411443950100_r31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.165.2.896","article-title":"IL-12 is required to maintain a Th1 response during Leishmania major infection","volume":"165","author":"Park","year":"2000","journal-title":"J. Immunol."},{"key":"2025032411443950100_r32","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/IAI.71.5.2498-2507.2003","article-title":"Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A","volume":"71","author":"Martin","year":"2003","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.colsurfb.2009.08.022","article-title":"Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations","volume":"75","author":"Anderson","year":"2009","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2025032411443950100_r34","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"2025032411443950100_r35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat. Immunol."},{"key":"2025032411443950100_r36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-065X.1989.tb00557.x","article-title":"Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease","volume":"112","author":"Scott","year":"1989","journal-title":"Immunol. Rev."},{"key":"2025032411443950100_r37","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1073\/pnas.92.8.3142","article-title":"Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam","volume":"92","author":"Nabors","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411443950100_r38","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1128\/IAI.72.8.4918-4923.2004","article-title":"Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major","volume":"72","author":"Da CostaSantiago","year":"2004","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r39","first-page":"801","article-title":"Pathogen-imposed skewing of mouse chemokine and cytokine expression at the infected tissue site","volume":"118","author":"Katzman","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025032411443950100_r40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chom.2009.04.014","article-title":"A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection","volume":"6","author":"Filipe-Santos","year":"2009","journal-title":"Cell Host Microbe"},{"key":"2025032411443950100_r41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"2025032411443950100_r42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"2025032411443950100_r43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0167-5699(93)90230-I","article-title":"Interleukin-12 and its role in the generation of TH1 cells","volume":"14","author":"Trinchieri","year":"1993","journal-title":"Immunol. Today"},{"key":"2025032411443950100_r44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(87)90116-4","article-title":"Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis","volume":"329","author":"Convit","year":"1987","journal-title":"Lancet"},{"key":"2025032411443950100_r45","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/infdis\/167.Supplement_1.S13","article-title":"The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis","volume":"167","author":"Badaro","year":"1993","journal-title":"J. Infect. Dis."},{"key":"2025032411443950100_r46","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/4000","article-title":"Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection","volume":"4","author":"Gurunathan","year":"1998","journal-title":"Nat. Med."},{"key":"2025032411443950100_r47","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/1521-4141(200111)31:11<3175::AID-IMMU3175>3.0.CO;2-L","article-title":"Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB\/c mice","volume":"31","author":"Uzonna","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"2025032411443950100_r48","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1128\/IAI.72.4.1920-1928.2004","article-title":"Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major","volume":"72","author":"Kropf","year":"2004","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r49","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1128\/IAI.72.9.5168-5174.2004","article-title":"Chemokine gene expression in Toll-like receptor-competent and -deficient mice infected with Leishmania major","volume":"72","author":"Antoniazi","year":"2004","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2006.03258.x","article-title":"Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin","volume":"147","author":"Sugita","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"2025032411443950100_r51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/sj.gt.3302240","article-title":"IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB\/c mice: is the effect mediated by the CpG signaling TLR9?","volume":"11","author":"Li","year":"2004","journal-title":"Gene Ther."},{"key":"2025032411443950100_r52","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1128\/IAI.01527-07","article-title":"Immunization with a Toll-like receptor 7 and\/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB\/c mice","volume":"76","author":"Zhang","year":"2008","journal-title":"Infect. Immun."},{"key":"2025032411443950100_r53","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4049\/jimmunol.178.2.1164","article-title":"MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists","volume":"178","author":"Bagchi","year":"2007","journal-title":"J. Immunol."},{"key":"2025032411443950100_r54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.imlet.2007.11.014","article-title":"Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells","volume":"116","author":"Vanhoutte","year":"2008","journal-title":"Immunol. Lett."},{"key":"2025032411443950100_r55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2005-10-4015","article-title":"Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo","volume":"108","author":"Warger","year":"2006","journal-title":"Blood"},{"key":"2025032411443950100_r56","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1158\/0008-5472.CAN-04-0063","article-title":"Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity","volume":"64","author":"Whitmore","year":"2004","journal-title":"Cancer Res."},{"key":"2025032411443950100_r57","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1086\/324161","article-title":"Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator","volume":"33","author":"Arevalo","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"2025032411443950100_r58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.exppara.2006.12.004","article-title":"Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod","volume":"116","author":"El-On","year":"2007","journal-title":"Exp. Parasitol."},{"key":"2025032411443950100_r59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/infdis\/157.5.973","article-title":"Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony","volume":"157","author":"Murray","year":"1988","journal-title":"J. Infect. Dis."},{"key":"2025032411443950100_r60","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pntd.0000491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist Imiquimod in combination with pentavalent antimony","volume":"3","author":"Miranda-Verastegui","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2025032411443950100_r61","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nri1964","article-title":"Tuning inflammation and immunity by chemokine sequestration: decoys and more","volume":"6","author":"Mantovani","year":"2006","journal-title":"Nat. Rev. Immunol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/185\/3\/1701\/61609667\/1000238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/185\/3\/1701\/61609667\/1000238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:39:00Z","timestamp":1743201540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/185\/3\/1701\/7977592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1000238","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,8]]},"published":{"date-parts":[[2010,8,1]]}}}